Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

98.64EUR
3 Aug 2015
Change (% chg)

-- (--)
Prev Close
€98.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,271,910
52-wk High
€99.83
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets,... (more)

Overall

Beta: 0.72
Market Cap(Mil.): €129,065.60
Shares Outstanding(Mil.): 1,317.90
Dividend: 2.85
Yield (%): 2.91

Financials

  SASY.PA Industry Sector
P/E (TTM): 30.23 37.25 40.68
EPS (TTM): 3.24 -- --
ROI: -- 16.52 15.78
ROE: -- 17.30 16.82
Search Stocks

Sanofi's diabetes sales slow, Genzyme's jump

PARIS - Sanofi reported lower second quarter sales for its strategic diabetes division on Thursday, hurt by continued pricing pressure in the United States, but it's biotech arm Genzyme recorded another quarter of double-digit growth, enabling the French drugmaker to beat forecasts overall.

30 Jul 2015

UPDATE 1-Sanofi's diabetes sales slow, Genzyme's jump

* CEO Brandicourt to unveil strategic plan on Nov.6, open to M&A

30 Jul 2015

CORRECTED-Sanofi's diabetes division sales slow in Q2, Genzyme jumps

PARIS, July 30 - Sanofi's diabetes division reported lower second-quarter sales hurt by pricing pressure in the United States but the French drugmaker's biotech arm Genzyme posted another quarter of double-digit growth.

30 Jul 2015

BRIEF-Zealand Pharma maintains its financial guidance for 2015

* Lixisenatide (Lyxumia) royalty revenue increased in Q2 2015 as Sanofi confirms the submission of a NDA in the US

30 Jul 2015

BRIEF-Zealand Pharma: Sanofi announces first LixiLan Phase III trial's primary study endpoint

* Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint

29 Jul 2015

Sanofi's combination diabetes drug hits goal in late-stage trial

PARIS - Sanofi said on Wednesday a first late-stage Phase III study of its LixiLan diabetes drug had met its main target, while another would be completed at the end of the third quarter.

29 Jul 2015

Sanofi's combination diabetes drug hits goal in late-stage trial

PARIS, July 29 - Sanofi said on Wednesday a first late-stage Phase III study of its LixiLan diabetes drug had met its main target, while another would be completed at the end of the third quarter.

29 Jul 2015

Sanofi links with Regeneron in $2.2 billion cancer drug push

- French drugmaker Sanofi said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals in the hot area of cancer immunotherapy.

28 Jul 2015

Sanofi links with Regeneron in $2.2 bln cancer drug push

July 28 - French drugmaker Sanofi said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals in the hot area of cancer immunotherapy.

28 Jul 2015

BRIEF-Sanofi to invest $2.17 bln in Regeneron cancer therapy collaboration

* Sanofi and Regeneron agree to jointly develop PD-1 and other new immuno-oncology antibodies -

28 Jul 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : GlobalData
£81.00
Provider : Finlabo SIM Spa
£7.00
Provider : S&P Capital IQ – STARS Reports
£82.00
Provider : Reuters Investment Profile
£10.00
Provider : Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks